Hyperphosphatemia and Cardiovascular Disease

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Mar 22

PMID 33748139

Citations 31

Authors

Chao Zhou

Zhengyu Shi

Nan Ouyang

Xiongzhong Ruan

Affiliations

Soon will be listed here.

Abstract

Hyperphosphatemia or even serum phosphate levels within the "normal laboratory range" are highly associated with increased cardiovascular disease risk and mortality in the general population and patients suffering from chronic kidney disease (CKD). As the kidney function declines, serum phosphate levels rise and subsequently induce the development of hypertension, vascular calcification, cardiac valvular calcification, atherosclerosis, left ventricular hypertrophy and myocardial fibrosis by distinct mechanisms. Therefore, phosphate is considered as a promising therapeutic target to improve the cardiovascular outcome in CKD patients. The current therapeutic strategies are based on dietary and pharmacological reduction of serum phosphate levels to prevent hyperphosphatemia in CKD patients. Large randomized clinical trials with hard endpoints are urgently needed to establish a causal relationship between phosphate excess and cardiovascular disease (CVD) and to determine if lowering serum phosphate constitutes an effective intervention for the prevention and treatment of CVD.

Citing Articles

Assessing the Role of Asymmetric Dimethylarginine in Endothelial Dysfunction: Insights Into Cardiovascular Risk Factors.

Sonkar S, Verma J, Sonkar G, Gupta A, Singh A, Vishwakarma P Cureus. 2025; 17(1):e77565.

PMID: 39958038 PMC: 11830118. DOI: 10.7759/cureus.77565.

Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: a systematic review and meta-analysis of 2251 patients.

Elnaga A, Serag I, Alsaied M, Khalefa B, Rajput J, Ramadan S Int Urol Nephrol. 2024; .

PMID: 39702842 DOI: 10.1007/s11255-024-04316-x.

Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.

Fang H, Chen C Am J Transl Res. 2024; 16(11):6980-6990.

PMID: 39678559 PMC: 11645603. DOI: 10.62347/WXBL2590.

Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider.

Schwartz G, Darling J J Adv Pract Oncol. 2024; :1-27.

PMID: 39563966 PMC: 11573117. DOI: 10.6004/jadpro.2024.15.8.2.

Accelerated calciprotein crystallization time (T50) is correlated with impaired lung diffusion capacity in systemic sclerosis.

Geroldinger-Simic M, Sohail A, Razazian M, Krennmayr B, Pernsteiner V, Putz T Front Immunol. 2024; 15:1425885.

PMID: 39399492 PMC: 11466802. DOI: 10.3389/fimmu.2024.1425885.

References

Mendoza J, Isakova T, Ricardo A, Xie H, Navaneethan S, Anderson A . Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012; 7(7):1155-62. PMC: 3386678. DOI: 10.2215/CJN.13281211. View

Adeney K, Siscovick D, Ix J, Seliger S, Shlipak M, Jenny N . Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2008; 20(2):381-7. PMC: 2637048. DOI: 10.1681/ASN.2008040349. View

Mendoza J, Isakova T, Cai X, Bayes L, Faul C, Scialla J . Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int. 2016; 91(3):711-719. PMC: 5313324. DOI: 10.1016/j.kint.2016.10.021. View

Hu M, Shi M, Cho H, Adams-Huet B, Paek J, Hill K . Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol. 2014; 26(6):1290-302. PMC: 4446876. DOI: 10.1681/ASN.2014050465. View

Ciceri P, Falleni M, Tosi D, Martinelli C, Cannizzo S, Marchetti G . Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. Int J Mol Sci. 2019; 20(23). PMC: 6928632. DOI: 10.3390/ijms20235925. View

Ellam T, Chico T . Phosphate: the new cholesterol? The role of the phosphate axis in non-uremic vascular disease. Atherosclerosis. 2011; 220(2):310-8. DOI: 10.1016/j.atherosclerosis.2011.09.002. View

Bozic M, Panizo S, Sevilla M, Riera M, Soler M, Pascual J . High phosphate diet increases arterial blood pressure via a parathyroid hormone mediated increase of renin. J Hypertens. 2014; 32(9):1822-32. DOI: 10.1097/HJH.0000000000000261. View

Ruospo M, Palmer S, Natale P, Craig J, Vecchio M, Elder G . Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018; 8:CD006023. PMC: 6513594. DOI: 10.1002/14651858.CD006023.pub3. View

Bar L, Feger M, Fajol A, Klotz L, Zeng S, Lang F . Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc Natl Acad Sci U S A. 2018; 115(22):5804-5809. PMC: 5984514. DOI: 10.1073/pnas.1800160115. View

10.

Da J, Xie X, Wolf M, Disthabanchong S, Wang J, Zha Y . Serum Phosphorus and Progression of CKD and Mortality: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2015; 66(2):258-65. DOI: 10.1053/j.ajkd.2015.01.009. View

11.

Scialla J, Wolf M . Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014; 10(5):268-78. DOI: 10.1038/nrneph.2014.49. View

12.

Shroff R, McNair R, Figg N, Skepper J, Schurgers L, Gupta A . Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008; 118(17):1748-57. DOI: 10.1161/CIRCULATIONAHA.108.783738. View

13.

El Husseini D, Boulanger M, Fournier D, Mahmut A, Bosse Y, Pibarot P . High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1. PLoS One. 2013; 8(1):e53393. PMC: 3537628. DOI: 10.1371/journal.pone.0053393. View

14.

Angelova P, Baev A, Berezhnov A, Abramov A . Role of inorganic polyphosphate in mammalian cells: from signal transduction and mitochondrial metabolism to cell death. Biochem Soc Trans. 2016; 44(1):40-5. DOI: 10.1042/BST20150223. View

15.

Tuzun D, Oguz A, Aydin M, Belge Kurutas E, Ercan O, Sahin M . Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes?. Arch Endocrinol Metab. 2018; 62(5):506-513. PMC: 10118658. DOI: 10.20945/2359-3997000000070. View

16.

Shobeiri N, Adams M, Holden R . Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol. 2013; 77(1):39-54. PMC: 3895346. DOI: 10.1111/bcp.12117. View

17.

Roy C, Lejeune S, Slimani A, de Meester C, Ahn As S, Rousseau M . Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2020; 7(5):2494-2507. PMC: 7524237. DOI: 10.1002/ehf2.12816. View

18.

Sikura K, Potor L, Szerafin T, Oros M, Nagy P, Mehes G . Hydrogen sulfide inhibits calcification of heart valves; implications for calcific aortic valve disease. Br J Pharmacol. 2019; 177(4):793-809. PMC: 7024713. DOI: 10.1111/bph.14691. View

19.

Shang D, Xie Q, Shang B, Zhang M, You L, Hao C . Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. Biomed Res Int. 2017; 2017:2520510. PMC: 5340948. DOI: 10.1155/2017/2520510. View

20.

Cozzolino M, Ciceri P, Galassi A, Mangano M, Carugo S, Capelli I . The Key Role of Phosphate on Vascular Calcification. Toxins (Basel). 2019; 11(4). PMC: 6521180. DOI: 10.3390/toxins11040213. View